Lipid profiles in schizophrenia associated with clinical traits: A five year follow-up study

BMC Psychiatry

Volumn 16, Issue 1, 2016, Pages

  Solberg, Dag K ^a,b   Bentsen, Håvard ^b   Refsum, Helge ^b   Andreassen, Ole A ^c,d  

^a Institute for Military Psychiatry   (Norway)

^b DIAKONHJEMMET HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LIPID; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL; MEMBRANE LIPID;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLOBAL ASSESSMENT OF FUNCTIONING; HOSPITAL ADMISSION; HOSPITAL PERSONNEL; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; STAGING; BLOOD; LONGITUDINAL STUDY; MIDDLE AGED; TIME FACTOR; TRENDS;

ADULT; CHOLESTEROL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; LONGITUDINAL STUDIES; MALE; MEMBRANE LIPIDS; MIDDLE AGED; PATIENT ADMISSION; SCHIZOPHRENIA; TIME FACTORS; TRIGLYCERIDES;

EID: 84983677646     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-016-1006-3     Document Type: Article

References (63)

1. Paton C, Esop R, Young C, Taylor D. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand. 2004;110(4):299-305.
2. Saari K, Jokelainen J, Veijola J, Koponen H, Jones PB, Savolainen M, et al. Serum lipids in schizophrenia and other functional psychoses: a general population northern Finland 1966 birth cohort survey. Acta Psychiatr Scand. 2004;110(4):279-85.
3. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19 Suppl 1:1-93.
4. Kaddurah-Daouk R, McEvoy J, Baillie R, Zhu H, Yao K, Nimgaonkar VL, et al. Impaired plasmalogens in patients with schizophrenia. Psychiatry Res. 2012;198(3):347-52.
5. Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, Koethe D, et al. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res. 2008;7(10):4266-77.
6. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl. 2004;47:S76-9.
7. Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry. 2009;70(7):997-1000.
8. Mahadik SP, Evans DR. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatr Clin North Am. 2003;26(1):85-102.
9. Bentsen H, Solberg DK, Refsum H, Gran JM, Bohmer T, Torjesen PA, et al. Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biol Psychiatry. 2011;70(1):97-105.
10. Hoen WP, Lijmer JG, Duran M, Wanders RJ, Van Beveren NJ, De HL. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: A meta-analysis. Psychiatry Res. 2013;207(1-2):1-12.
11. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res. 2002;58(1):1-10.
12. Montesinos-Rueda L, Canete-Crespillo J, Palma-Sevillano C, Gine-Serven E. Erythrocyte membrane polyunsaturated fatty acid (pufa) levels in a sample of patients with schizophrenia and relation with clinical and progression variables. Actas Esp Psiquiatr. 2015;43(5):170-6.
13. van der Kemp WJ, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. Schizophr Res. 2012;141(2-3):153-61.
14. Woods AG, Sokolowska I, Taurines R, Gerlach M, Dudley E, Thome J, et al. Potential biomarkers in psychiatry: focus on the cholesterol system. J Cell Mol Med. 2012;16(6):1184-95.
15. Weber-Fahr W, Englisch S, Esser A, Tunc-Skarka N, Meyer-Lindenberg A, Ende G, et al. Altered phospholipid metabolism in schizophrenia: a phosphorus 31 nuclear magnetic resonance spectroscopy study. Psychiatry Res. 2013;214(3):365-73.
16. Anderson G, Maes M, Berk M. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:101-14.
17. Grima G, Benz B, Parpura V, Cuenod M, Do KQ. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr Res. 2003;62(3):213-24.
18. Horrobin DF, Glen AI, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res. 1994;13(3):195-207.
19. Nuss P, Tessier C, Ferreri F, De HM, Peuskens J, Trugnan G, et al. Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia. Psychiatry Res. 2009;169(2):91-6.
20. Dietrich-Muszalska A, Kontek B. Lipid peroxidation in patients with schizophrenia. Psychiatry Clin Neurosci. 2010;64(5):469-75.
21. Wu JQ, Kosten TR, Zhang XY. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:200-6.
22. Le LS, Simard G, Martinez MC, Andriantsitohaina R. Oxidative stress and metabolic pathologies: from an adipocentric point of view. Oxid Med Cell Longev. 2014;2014:908539.
23. Podrez EA. Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin Exp Pharmacol Physiol. 2010;37(7):719-25.
24. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84(21-22):705-12.
25. Mahadik SP, Mukherjee S, Correnti EE, Kelkar HS, Wakade CG, Costa RM, et al. Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophr Res. 1994;13(3):239-47.
26. Solberg DK, Bentsen H, Refsum H, Andreassen OA. Association between serum lipids and membrane fatty acids and clinical characteristics in patients with schizophrenia. Acta Psychiatr Scand. 2015;132(4):293-300.
27. Du Bois TM, Deng C, Huang XF. Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(6):878-88.
28. Procyshyn RM, Wasan KM, Thornton AE, Barr AM, Chen EY, Pomarol-Clotet E, et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci. 2007;32(5):331-8.
29. Sumiyoshi T, Higuchi Y, Matsui M, Itoh H, Uehara T, Itoh T, et al. Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia. Psychiatry Res. 2011;186(1):23-7.
30. Bentsen H, Osnes K, Refsum H, Solberg DK, Bohmer T. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia. Transl Psychiatry. 2013;3, e335.
31. Van der Gaag M, Hoffman T, Remijsen M, Hijman R, De HL, Van MB, et al. The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res. 2006;85(1-3):280-7.
32. Pedersen G, Karterud S. The symptom and function dimensions of the Global Assessment of Functioning (GAF) scale. Compr Psychiatry. 2012;53(3):292-8.
33. Bentsen H, Solberg DK, Refsum H, Bohmer T. Clinical and biochemical validation of two endophenotypes of schizophrenia defined by levels of polyunsaturated fatty acids in red blood cells. Prostaglandins Leukot Essent Fatty Acids. 2012;87(1):35-41.
34. Fernandes BS, Steiner J, Bernstein HG, Dodd S, Pasco JA, Dean OM, et al. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry. 2016;21(4):554-64.
35. Goff DC, Romero K, Paul J, Mercedes Perez-Rodriguez M, Crandall D, Potkin SG. Biomarkers for drug development in early psychosis: Current issues and promising directions. Eur Neuropsychopharmacol. 2016;19.
36. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev. 2010;12, CD006629.
37. Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry. 2000;47(1):8-21.
38. McEvoy J, Baillie RA, Zhu H, Buckley P, Keshavan MS, Nasrallah HA, et al. Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PLoS One. 2013;8(7), e68717.
39. Assies J, Mocking RJ, Lok A, Ruhe HG, Pouwer F, Schene AH. Effects of oxidative stress on fatty acid-and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity. Acta Psychiatr Scand. 2014;130(3):163-80.
40. Krakowski M, Czobor P. Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol. Schizophr Res. 2011;130(1-3):27-33.
41. Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O'Donovan MC, et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet. 2013;92(2):197-209.
42. Salim S. Oxidative stress and psychological disorders. Curr Neuropharmacol. 2014;12(2):140-7.
43. Vidovic B, Stefanovic A, Milovanovic S, Ethordevic B, Kotur-Stevuljevic J, Ivanisevic J, et al. Associations of oxidative stress status parameters with traditional cardiovascular disease risk factors in patients with schizophrenia. Scand J Clin Lab Invest. 2014;74(3):184-91.
44. Muller N, Weidinger E, Leitner B, Schwarz MJ. The role of inflammation in schizophrenia. Front Neurosci. 2015;9:372.
45. Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev. 2011;35(3):878-93.
46. Tsaluchidu S, Cocchi M, Tonello L, Puri BK. Fatty acids and oxidative stress in psychiatric disorders. BMC Psychiatry. 2008;8(1):S5.
47. Fournier M, Ferrari C, Baumann PS, Polari A, Monin A, Bellier-Teichmann T, et al. Impaired metabolic reactivity to oxidative stress in early psychosis patients. Schizophr Bull. 2014;40(5):973-83.
48. Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015;2(3):258-70.
49. Trepanier MO, Hopperton KE, Mizrahi R, Mechawar N, Bazinet RP. Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Mol Psychiatry. 2016;7.
50. Najjar S, Pearlman DM. Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res. 2015;161(1):102-12.
51. Coughlin JM, Wang Y, Ambinder EB, Ward RE, Minn I, Vranesic M, et al. In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11) C] DPA-713 PET and analysis of CSF and plasma. Transl Psychiatry. 2016;6, e777.
52. Morch RH, Dieset I, Faerden A, Hope S, Aas M, Nerhus M, et al. Inflammatory evidence for the psychosis continuum model. Psychoneuroendocrinology. 2016;67:189-97.
53. Hope S, Ueland T, Steen NE, Dieset I, Lorentzen S, Berg AO, et al. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res. 2013;145(1-3):36-42.
54. Siasos G, Tousoulis D, Oikonomou E, Zaromitidou M, Stefanadis C, Papavassiliou AG. Inflammatory markers in hyperlipidemia: from experimental models to clinical practice. Curr Pharm Des. 2011;17(37):4132-46.
55. Fritsche KL. The science of fatty acids and inflammation. Adv Nutr. 2015;6(3):293S-301S.
56. Andreassen OA, Desikan RS, Wang Y, Thompson WK, Schork AJ, Zuber V, et al. Abundant genetic overlap between blood lipids and immune-mediated diseases indicates shared molecular genetic mechanisms. PLoS One. 2015;10(4), e0123057.
57. Dieset I, Hope S, Ueland T, Bjella T, Agartz I, Melle I, et al. Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. Schizophr Res. 2012;140(1-3):169-74.
58. Robichaud PP, Surette ME. Polyunsaturated fatty acid-phospholipid remodeling and inflammation. Curr Opin Endocrinol Diabetes Obes. 2015;22(2):112-8.
59. Rao JS, Kim HW, Harry GJ, Rapoport SI, Reese EA. Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophr Res. 2013;147(1):24-31.
60. Yagami T, Koma H, Yamamoto Y. Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System. Mol Neurobiol. 2015;6(28):26437-56.
61. Janssen CI, Kiliaan AJ. Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration. Prog Lipid Res. 2014;53:1-17.
62. Fernandez-Perez EJ, Peters C, Aguayo LG. Membrane Damage Induced by Amyloid Beta and a Potential Link with Neuroinflammation. Curr Pharm Des. 2016;22(10):1295-304.
63. Gamba P, Testa G, Gargiulo S, Staurenghi E, Poli G, Leonarduzzi G. Oxidized cholesterol as the driving force behind the development of Alzheimer's disease. Front Aging Neurosci. 2015;7:119.